Quantcast

Tianyin Pharmaceutical Co. Inc. Completes Construction of New Production Facility

May 7, 2009

CHENGDU, China, May 7 /PRNewswire-Asia-FirstCall/ — Tianyin
Pharmaceutical, Co., Inc., (NYSE Amex: TPI), a manufacturer and supplier of
modernized traditional Chinese medicine (“TCM”) based in Chengdu, China, today
announced that it has completed construction of their new production facility
in Chengdu and the expansion project has entered into the testing production
phase.

All of the new equipment has been installed in the new production facility
and Tianyin is currently testing the purification system. The Company expects
to complete the testing phase later this month. The new production facility is
expected to triple the production capacity of solid dosage drugs, such as
Azithromycin Dispersible Tablets, Mycophenolate Mofetil Capsules, and Dantong
Capsules.

“The completion of construction of our new production facility represents
an important milestone in our expansion project. The new facility will
accommodate increasing production volumes and expected future growth,” Dr.
Jiang Guoqing, Tianyin’s Chairman and CEO commented. “We are on track to
complete the expansion project and launch the new facility in July 2009, which
we expect to further drive market share gains and provide incremental growth
of our revenue in fiscal 2010 and beyond. We remain committed to maximizing
the value and growth potential of our business and ultimately increase
shareholder value.”

About Tianyin Pharmaceuticals

Tianyin is a manufacturer and supplier of modernized Traditional Chinese
Medicine (“TCM”) in China. It was established in 1994 and acquired by the
current management team in August 2003. It has a comprehensive product
portfolio of 33 modernized TCMs and 5 generic western medicines in the market,
22 of which are listed in the highly selective National Medicine Catalog of
the National Medical Insurance Program. Tianyin owns and operates two GMP
manufacturing facilities and an R&D platform supported by leading Chinese
academic institutions. The Company has a pipeline of 47 pharmaceutical
products pending approval. Tianyin has an extensive nationwide distribution
network throughout China with a sales force of 720 salespeople. Tianyin is
headquartered in Chengdu, Sichuan Province with two manufacturing facilities
and a total of 1,365 employees. Tianyin achieved revenue of approximately
$33.5 million and net income of approximately $6 million in FY2008 ending June
30, 2008
. For more information about Tianyin, please visit
http://www.tianyinpharma.com .

Safe Harbor Statement

The Statements which are not historical facts contained in this press
release are forward-looking statements that involve certain risks and
uncertainties including but not limited to risks associated with the
uncertainty of future financial results, additional financing requirements,
development of new products, government approval processes, the impact of
competitive products or pricing, technological changes, the effect of economic
conditions and other uncertainties detailed in the Company’s filings with the
Securities and Exchange Commission.

    For more information, please contact:

    For the Company:
     Allen Tang, Ph.D., MBA, Assistant to the CEO
     China
     Tel:   +86-158-2122-5642
     Email: Allen.y.tang@gmail.com

    Investors:
    Mr. Matthew Hayden, HC International
    Tel:   +1-561-245-5155
    Email: matt.hayden@hcinternational.net
    Web:   http://www.hcinternational.net

SOURCE Tianyin Pharmaceutical, Co., Inc.


Source: newswire



comments powered by Disqus